Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Diffusion Pharmaceuticals Inc. (DFFN)
|
Add to portfolio |
|
|
|
| Price: |
$0.33
| | Metrics |
| OS: |
2.04
|
M
| |
|
|
| Market cap: |
$663.9
|
k
| |
|
|
|
Net cash:
|
$15
|
M
| |
$7.35
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 37.9 | 22.7 | 36.7 | 12.8 |
| Revenue growth | | | | -100.0% | 67.1% | -38.2% | 186.8% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 37.9 | 22.7 | 36.7 | 12.8 |
| Gross margin | | | | | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 7.2 | 8.5 | 9.4 | 6.6 | 5.8 | 5.1 | 7.3 | 3.9 |
| General and administrative | 8.7 | 7.4 | 6.4 | 4.8 | 6.2 | 6.2 | 11.1 | 2.5 |
| EBIT | -16.0 | -16.0 | -16.0 | -11.6 | 25.9 | 11.3 | 18.4 | 6.4 |
| EBIT margin | | | | | 68.3% | 50.0% | 50.0% | 50.0% |
| Pre-tax income | -15.6 | -24.5 | -15.9 | -11.5 | -18.8 | -2.4 | -18.4 | -6.7 |
| Income taxes | 0.0 | -0.4 | -1.7 | 0.3 | -0.4 | -1.1 | -0.4 | 0.0 |
| Tax rate | 0.0% | 1.8% | 10.6% | | 2.3% | 43.6% | 2.0% | 0.0% |
| Net income | -15.6 | -24.1 | -16.1 | -11.8 | -26.6 | -2.6 | -18.0 | -6.7 |
| Net margin | | | | | -70.2% | -11.5% | -49.1% | -52.4% |
| |
| Diluted EPS | ($7.65) | ($12.38) | ($0.30) | ($1.76) | ($8.21) | ($3.09) | ($1.76) | ($2.56) |
| Shares outstanding (diluted) | 2.0 | 1.9 | 53.8 | 6.7 | 3.2 | 0.8 | 10.2 | 2.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|